Bell Bank Gilead Sciences, Inc. Transaction History

Bell Bank

$1.18 Billion
Q2 2024

A detailed history of Bell Bank transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bell Bank holds 132,473 shares of GILD stock, worth $10.4 Million. This represents 0.77% of its overall portfolio holdings.

Number of Shares

132,473

Previous 128,251 3.29%

Holding current value

$10.4 Million

Previous $9.39 Million 3.26%

% of portfolio

0.77%

Previous 0.82%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$63.15 - $72.88 $266,619 - $307,699	4,222 Added 3.29%	132,473 $9.09 Million
Q1 2024 Apr 23, 2024	BUY	$71.58 - $87.29 $330,556 - $403,105	4,618 Added 3.74%	128,251 $9.39 Million
Q4 2023 Jan 22, 2024	SELL	$73.27 - $83.09 $31,799 - $36,061	-434 Reduced 0.35%	123,633 $10 Million
Q3 2023 Oct 30, 2023	BUY	$73.94 - $80.67 $57,821 - $63,083	782 Added 0.63%	124,067 $9.3 Million
Q2 2023 Jul 26, 2023	SELL	$76.01 - $86.7 $355,118 - $405,062	-4,672 Reduced 3.65%	123,285 $9.5 Million
Q1 2023 Apr 19, 2023	SELL	$77.31 - $88.08 $694,475 - $791,222	-8,983 Reduced 6.56%	127,957 $10.6 Million
Q4 2022 Jan 31, 2023	SELL	$62.32 - $89.47 $448,143 - $643,378	-7,191 Reduced 4.99%	136,940 $11.8 Million
Q3 2022 Oct 11, 2022	BUY	$59.54 - $68.01 $995,389 - $1.14 Million	16,718 Added 13.12%	144,131 $8.89 Million
Q2 2022 Jul 15, 2022	BUY	$57.72 - $65.01 $603,578 - $679,809	10,457 Added 8.94%	127,413 $7.88 Million
Q1 2022 Apr 25, 2022	BUY	$57.92 - $72.58 $6.77 Million - $8.49 Million	116,956 New	116,956 $6.95 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $1.45 Million - $1.68 Million	-20,040 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$62.63 - $80.22 $1.26 Million - $1.61 Million	20,040 New	20,040 $1.5 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $98.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Bank, based on Form 13F filings with the SEC.

News

Stay updated on Bell Bank with notifications on news.

Account